Z-DL-phenylalanine
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-DL-phenylalanine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
CBZ-Amino Acids
Catalog number
BAT-003300
CAS number
3588-57-6
Molecular Formula
C17H17NO4
Molecular Weight
299.30
Z-DL-phenylalanine
IUPAC Name
3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid
Synonyms
Z-DL-Phe-OH; 2-([(Benzyloxy)carbonyl]amino)-3-phenylpropanoic acid
Appearance
White crystalline powder
Purity
≥ 99% (HPLC)
Density
1.248±0.06 g/cm3(Predicted)
Melting Point
95-105 °C
Boiling Point
511.5±50.0 °C(Predicted)
Storage
Store at 2-8°C
InChI
InChI=1S/C17H17NO4/c19-16(20)15(11-13-7-3-1-4-8-13)18-17(21)22-12-14-9-5-2-6-10-14/h1-10,15H,11-12H2,(H,18,21)(H,19,20)
InChI Key
RRONHWAVOYADJL-UHFFFAOYSA-N
Canonical SMILES
C1=CC=C(C=C1)CC(C(=O)O)NC(=O)OCC2=CC=CC=C2
1. The polymorphs of L-phenylalanine
Franziska Stefanie Ihlefeldt, Fredrik Bjarte Pettersen, Aidan von Bonin, Malgorzata Zawadzka, Carl Henrik Görbitz Angew Chem Int Ed Engl. 2014 Dec 1;53(49):13600-4. doi: 10.1002/anie.201406886. Epub 2014 Oct 21.
The solid-state structure of the amino acid phenylalanine (Phe) offers a potential key to understanding the behavior of a large class of important aromatic compounds. Obtaining good single crystals is, however, notoriously difficult. The structure of the common polymorph of Phe, form I, was first reported by Weissbuch et al. (as D-Phe) in 1990, but the correctness of the published C2 unit cell with two disordered molecules in the asymmetric unit was later questioned and other space groups suggested. The identity of form I of L-Phe is here established to be P21 with Z'=4, based on data from a well-diffracting single crystal grown from an acetic acid solution of the amino acid. A second new polymorph, form IV, together with the two recently described forms II and III provide unprecedented information on the structural complexity of this essential amino acid. It is furthermore documented that the racemate, dl-Phe, does not grow proper single crystals.
2. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors
Ina Nemet, et al. Cell. 2020 Mar 5;180(5):862-877.e22. doi: 10.1016/j.cell.2020.02.016.
Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independent cohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction, stroke, or death). A gut microbiota-derived metabolite, PAGln, was shown to enhance platelet activation-related phenotypes and thrombosis potential in whole blood, isolated platelets, and animal models of arterial injury. Functional and genetic engineering studies with human commensals, coupled with microbial colonization of germ-free mice, showed the microbial porA gene facilitates dietary phenylalanine conversion into phenylacetic acid, with subsequent host generation of PAGln and phenylacetylglycine (PAGly) fostering platelet responsiveness and thrombosis potential. Both gain- and loss-of-function studies employing genetic and pharmacological tools reveal PAGln mediates cellular events through G-protein coupled receptors, including α2A, α2B, and β2-adrenergic receptors. PAGln thus represents a new CVD-promoting gut microbiota-dependent metabolite that signals via adrenergic receptors.
3. Dysregulated Phenylalanine Catabolism Plays a Key Role in the Trajectory of Cardiac Aging
Gabor Czibik, et al. Circulation. 2021 Aug 17;144(7):559-574. doi: 10.1161/CIRCULATIONAHA.121.054204. Epub 2021 Jun 24.
Background: Aging myocardium undergoes progressive cardiac hypertrophy and interstitial fibrosis with diastolic and systolic dysfunction. Recent metabolomics studies shed light on amino acids in aging. The present study aimed to dissect how aging leads to elevated plasma levels of the essential amino acid phenylalanine and how it may promote age-related cardiac dysfunction. Methods: We studied cardiac structure and function, together with phenylalanine catabolism in wild-type (WT) and p21-/- mice (male; 2-24 months), with the latter known to be protected from cellular senescence. To explore phenylalanine's effects on cellular senescence and ectopic phenylalanine catabolism, we treated cardiomyocytes (primary adult rat or human AC-16) with phenylalanine. To establish a role for phenylalanine in driving cardiac aging, WT male mice were treated twice a day with phenylalanine (200 mg/kg) for a month. We also treated aged WT mice with tetrahydrobiopterin (10 mg/kg), the essential cofactor for the phenylalanine-degrading enzyme PAH (phenylalanine hydroxylase), or restricted dietary phenylalanine intake. The impact of senescence on hepatic phenylalanine catabolism was explored in vitro in AML12 hepatocytes treated with Nutlin3a (a p53 activator), with or without p21-targeting small interfering RNA or tetrahydrobiopterin, with quantification of PAH and tyrosine levels. Results: Natural aging is associated with a progressive increase in plasma phenylalanine levels concomitant with cardiac dysfunction, whereas p21 deletion delayed these changes. Phenylalanine treatment induced premature cardiac deterioration in young WT mice, strikingly akin to that occurring with aging, while triggering cellular senescence, redox, and epigenetic changes. Pharmacological restoration of phenylalanine catabolism with tetrahydrobiopterin administration or dietary phenylalanine restriction abrogated the rise in plasma phenylalanine and reversed cardiac senescent alterations in aged WT mice. Observations from aged mice and human samples implicated age-related decline in hepatic phenylalanine catabolism as a key driver of elevated plasma phenylalanine levels and showed increased myocardial PAH-mediated phenylalanine catabolism, a novel signature of cardiac aging. Conclusions: Our findings establish a pathogenic role for increased phenylalanine levels in cardiac aging, linking plasma phenylalanine levels to cardiac senescence via dysregulated phenylalanine catabolism along a hepatic-cardiac axis. They highlight phenylalanine/PAH modulation as a potential therapeutic strategy for age-associated cardiac impairment.
Online Inquiry
Verification code
Inquiry Basket